Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 9/20 | 0.47 |
| ▸ | IL2 | P60568 | 9/20 | 0.47 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25517799 | 0.90 | TAS1R3 (0.47) | ALBIL2F2R | |
| SCHEMBL25232548 | 0.87 | KMT2A (0.58) | ALBIL2 | |
| SCHEMBL25232550 | 0.87 | KMT2A (0.58) | ALBIL2 | |
| SCHEMBL25224163 | 0.83 | CCKBR (0.61) | GRNSORT1PYGLALBIL2 | |
| SCHEMBL30174883 | 0.83 | CCKBR (0.61) | GRNSORT1PYGLALBIL2 | |
| SCHEMBL25194705 | 0.83 | CCKBR (0.61) | GRNSORT1PYGLALBIL2 | |
| SCHEMBL25517406 | 0.83 | CCKBR (0.61) | GRNSORT1PYGLALBIL2 | |
| SCHEMBL30310299 | 0.81 | KMT2A (0.61) | ALBIL2 | |
| SCHEMBL30310555 | 0.81 | KMT2A (0.61) | ALBIL2 | |
| SCHEMBL23824473 | 0.81 | KMT2A (0.61) | ALBIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | GRN 2468/4885SORT1 4606/4885PYGL 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.